* For a separate FACTBOX on all the coronavirus vaccines
under
development, click
(Adds UK approval of Pfizer/BioNTech vaccine, developments on
other candidates)
Dec 2 (Reuters) - Britain approved the Pfizer-BioNTech
COVID-19 vaccine for use on Wednesday with
roll-out expected early next week, becoming the first western
country to give such authorisation.
Pfizer-BioNTech and U.S.-based Moderna Inc also
applied for emergency European Union approval for their
respective vaccines on Tuesday, while they have also sought
similar use for their shots in the United States.
Moderna has said its COVID-19 vaccine was 94.1% effective
with no serious safety concerns, according to full results from
a late-stage study.
The vaccine developed by Pfizer and BioNTech
has showed a 95% efficacy rate.
Russia has said its Sputnik V vaccine showed 92%
effectiveness, while Britain's AstraZeneca announced an
average efficacy rate of 70%.
More than 150 potential vaccines are being developed and
tested globally to stop the COVID-19 pandemic, with 48 in human
trials, according to the World Health Organization (WHO).
The following list tracks the candidates that are in the
final stages of testing.
COMPANY STAGE OF DEVELOPMENT EXPECTED DOSES
Pfizer Inc & Approved for use in the UK; (Nine countries for over 600 mln
BioNTech SE applied for emergency approvals doses)
in the European Union and the
United States. U.S.- 100 mln + option for 500
mln more UK - 40 mln; expects to have 10
mln doses by end of 2020 EU - 300 mln, to start by end of
2020 Canada - Minimum of 20 mln doses Japan - 120 mln
Moderna Inc Full results from a late-stage U.S.- 100 mln + option for
study showed the vaccine's additional 400 mln
efficacy rate was consistent
across age, race and ethnicity EU- 80 mln
and had a 100% success rate in
preventing severe COVID-19 cases. UK - 7 mln
The company has applied for
emergency approvals in EU and Japan- 50 mln or more, to be
U.S. distributed by Takeda Canada- 20 mln Johnson & Johnson Health regulators in Europe and U.S.- 100 mln + 200 mln more
Canada have started a real-time under subsequent agreement
review of vaccine after
preliminary results showed the UK- 30 mln + option for up to 22
shot triggered the production of mln more
antibodies and immune cells
against the virus. EU- 200 mln + 200 mln additional Canada- Up to 38 mln Japan- Not Applicable
AstraZeneca Plc & Vaccine could be around 90% (15 countries and groups for over
Oxford University effective in preventing COVID-19 3 bln doses)
without any serious side effects,
when it was administered as a U.S.- 300 mln
half dose followed by a full dose
at least one month apart. UK- 4 mln doses this year
(delivery schedule pushed back
after trial results; earlier 30
mln doses were expected with
initial deliveries by Sept/Oct.
2020) EU- At least 300 mln + 100 mln
additional Italy, Germany, the Netherlands
and France - 300 mln + 100 mln
additional Canada- Up to 20 mln Japan- 120 mln Bangladesh - 30 mln (through
India's Serum Institute)
Sinovac Biotech Ltd Late-stage trials under way in Vaccine approved for emergency
Brazil, Indonesia and Turkey; use in China in July; supply
interim results on efficiency deals with Indonesia for 40 mln
from Brazil trial expected in doses before Mar 2021, and with
early December. Brazil for 46 mln doses; Turkey
plans to sign a contract to buy
at least 20 mln doses
Gamaleya Research Institute Russia said its Sputnik V vaccine Supply deals with over 10
is 92% effective at protecting countries including India, Brazil
people from COVID-19. It has also and Argentina for at least 280
announced plans to vaccinate over mln doses
400,000 military personnel
against COVID-19.
CanSino Biologics Inc Approved for use in Chinese Mexico - 35 mln doses as early as
military. Late-stage trial Dec
underway in Pakistan and Mexico. Sinopharm Group Co Ltd Nearly one million people have Expects to produce more than 1
taken the vaccine developed by bln doses in 2021
Sinopharm through the country's
emergency use programme. The
company has said data from
late-stage clinical trials for
its vaccine are "better than
expected".
(Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy,
Vishwadha Chander, Manas Mishra and Muvija M in Bengaluru;
editing by Ankur Banerjee, Ramakrishnan M., Sriraj Kalluvila,
Maju Samuel and Aditya Soni)
我们的标准: 汤森路透“信任原则”